{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:54:03Z","timestamp":1783000443434,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.neurol.2021.02.393","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T12:02:33Z","timestamp":1624536153000},"page":"1241-1249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy"],"prefix":"10.1016","volume":"177","author":[{"given":"D.","family":"Guery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Durand-Dubief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Guerrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2021.02.393_bib0130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2021.02.393_bib0140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2021.02.393_bib0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O\u2019Connor","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.02.393_bib0150","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","article-title":"Natalizumab therapy for highly active pediatric multiple sclerosis","volume":"70","author":"Kornek","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejpn.2012.09.004","article-title":"Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis","volume":"17","author":"Arnal-Garcia","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0160","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","article-title":"Safety and efficacy of natalizumab in children with multiple sclerosis","volume":"75","author":"Ghezzi","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.02.393_bib0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00415-019-09554-z","article-title":"No evidence of disease activity including cognition (NEDA-3 plus) in na\u00efve pediatric multiple sclerosis patients treated with natalizumab","volume":"267","author":"Margoni","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ene.12204","article-title":"A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort","volume":"21","author":"Outteryck","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jns.2016.03.025","article-title":"Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis","volume":"364","author":"Prosperini","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2021.02.393_bib0180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ane.12864","article-title":"Real-life clinical use of natalizumab and fingolimod in Austria","volume":"137","author":"Guger","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2021.02.393_bib0185","first-page":"7290285","article-title":"Real-Life Outcome in Multiple Sclerosis in the Czech Republic","volume":"2019","author":"Kobelt","year":"2019","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.neurol.2021.02.393_bib0190","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3389\/fneur.2018.01071","article-title":"Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0195","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","article-title":"EDMUS, a European database for multiple sclerosis","volume":"55","author":"Confavreux","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2021.02.393_bib0200","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.02.393_bib0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1177\/1352458516630823","article-title":"False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients","volume":"22","author":"Cohen","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.02.393_bib0210","first-page":"94","article-title":"Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurol","volume":"77","author":"Vukusic","year":"2020"},{"key":"10.1016\/j.neurol.2021.02.393_bib0215","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","article-title":"A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2021.02.393_bib0220","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaci.2016.09.014","article-title":"Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site","volume":"139","author":"van Schie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0225","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.02.393_bib0230","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458511404271","article-title":"Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab","volume":"17","author":"S\u00f8rensen","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.02.393_bib0235","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2021.02.393_bib0240","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.02.393_bib0245","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2021.02.393_bib0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neurad.2014.12.001","article-title":"Imaging Working Group of the Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques. OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol","volume":"42","author":"Cotton","year":"2015","journal-title":"J Neuroradiol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872100583X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872100583X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:42:31Z","timestamp":1758519751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872100583X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S003537872100583X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.02.393","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.02.393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}